Though Kymera Therapeutics is increasing its cash burn and s...
Though Kymera Therapeutics is increasing its cash burn and seeing reduced operating revenue, it's still well positioned. However, potential share dilution from issuing new shares to cover a year's operations could deter future investors.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more